31.4 C
Vientiane
Monday, October 6, 2025
spot_img
Home Blog Page 148

NOARK Showcased at RE+ 2025 and NECA 2025 to Empower the Development of Renewable Energy and Electrical Industry

NOARK Showcased Renewable Energy Breakthroughs at RE+ 2025, Las Vegas

CHICAGO, Sept. 19, 2025 /PRNewswire/ — NOARK Electric, a global leader in circuit protection, motor control, and power distribution solutions, showcased at RE+ 2025, Las Vegas.

Renewable Energy Solutions of NOARK

NOARK brought renewable energy to life with two must-see highlights:

  • 3D Life-Size Natural Ester Oil-Filled Transformer Model — View a full-scale model to understand how NOARK’s transformer technology powers critical applications.
  • Interactive “Sand Table” Demo — Explore dynamic scenarios where electrical grids are powered up by NOARK’s transformers, switchboards, and circuit protection solutions, simulating real-world renewable energy and T&D challenges.

Our solution spans AC Grid-Connected systems, Energy Storage solutions and EV Charging infrastructure with products like Circuit Protection Breakers, Switches, Contactors, LV Switchboards, HV Oil-filled power transformers, HV insulators, MV Pad Mounted Transformers, MV fuse Cut-outs and Surge Arresters.

Meeting the Challenges of Renewable Energy Industry

These products of NOARK are engineered to deliver superior safety, durability, and efficiency. NOARK’s solutions help overcome industry challenges by providing robust and adaptable technologies that support the integration of renewable sources, and ensure continuous power delivery. With a focus on proven reliability and innovation, NOARK empowers utilities and developers to build efficient, future-ready clean energy systems globally.

NOARK illustrates how these solutions work together to overcome real-world challenges in renewable integration and transmission. By delivering robust, UL-certified, and interoperable systems, NOARK helps developers, utilities, and EPC contractors reduce downtime, lower lifetime costs, and accelerate the transition to a more reliable and sustainable energy future.

“At NOARK, we believe renewable energy requires not just vision, but proven, reliable technology that keeps grids resilient and efficient,” said Patrick Woodham, General Manager, USA and Canada, NOARK Electric. “We are proud to showcase how our transformers, circuit protection, and control solutions power the future of clean energy.”

NOARK Showcased Next-Gen Technology at NECA 2025, Chicago

NOARK Electric, a global manufacturer and supplier of low, medium and high-voltage electrical solutions for OEMs, contractors, and distributors, brought its cutting-edge Ex9VF7 Variable Frequency Drives (VFDs) at NECA 2025, Chicago.


Spotlight Product: Ex9VF7 Variable Frequency Drives

Engineered for precision, performance, and energy efficiency, key benefits of NOARK’s Ex9VF7 VFDs include:

  • Innovation & Design
    Advanced DSP technology for high-tech motor control
    Compact design for seamless Panel/MCC integration
    Flexible inverter control with customizable I/O mapping
  • Performance & Reliability
    Automated carrier wave oscillation for reduced audible noise
    Automated torque profiling for high-torque, low-speed applications
    NEMA 1 enclosure (IP20 protection)
  • Certifications & Connectivity
    UL 61800-5-1 (US & Canada certified)
    BACnet, Ethernet IP, CANopen, and Modbus communication options

Available in operational voltages ranging from Single-phase 110V to Three-phase 600V, the Ex9VF7 covers power ratings from 0.4kW to 185kW (0.25HP–250HP)—making it a versatile choice for pumps, fans, conveyors, and other industrial applications.

Why NOARK VFDs Matter in Today’s Industry

NOARK’s VFDs are more than just components—they’re intelligent systems enhancing operational efficiency and sustainability. They achieve this by:

  • Optimizing Motor Operation:
    Continuously monitoring motor performance and adjusting output in real-time—notably through a control loop that ensures precise speed and power delivery.
  • Boosting Efficiency & Longevity:
    By aligning motor output to actual demand, VFDs avoid energy waste and minimize mechanical stress, thereby extending equipment life.
  • Delivering Long-Term Value:
    While VFDs may require more upfront investment and expertise, their returns in productivity, maintenance savings, and operational control far outweigh the initial costs.

Meeting the Challenges of Electrification

NOARK Electric addresses critical challenges facing the modern power industry by delivering intelligent, high-efficiency, and reliably certified solutions. Our products are engineered to enhance grid stability, reduce energy waste, and simplify integration in complex industrial and commercial environments. For instance, the Ex9VF7 VFD optimizes motor-driven systems with precision control, significantly lowering power consumption in pumps, fans, and conveyors—directly tackling energy inefficiency.

Our UL-certified Pad Mount Transformers and modular LV Switchboards offer robust, safe, and adaptable power distribution, enabling seamless expansion in data centers, renewable integration, and facility upgrades. With advanced communication capabilities and standardized certifications, NOARK ensures interoperability and future-ready performance, empowering operators and contractors to meet evolving demands for reliability, sustainability, and cost-effective electrical infrastructure.

NOARK is committed to empowering the electrical industry with innovative, efficient, and reliable solutions—designed with electrical contractors in mind,” said Patrick Woodham, General Manager, USA and Canada, NOARK Electric. “Events like the NECA Conference give us the opportunity to connect directly with customers, demonstrate our technology, and reinforce our mission of redefining standards through innovation.”

Innovent Announces Mazdutide Received Approval from China’s NMPA for Glycemic Control in Adults with Type 2 Diabetes

SAN FRANCISCO and SUZHOU, China, Sept. 19, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that China’s National Medical Products Administration (NMPA) has approved mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, for glycemic control in adults with type 2 diabetes (T2D). Mazdutide is the world’s first dual GCG/GLP-1 receptor agonist approved for glycemic control in adults with T2D. It is expected to support disease management for the vast T2D population in China, achieving comprehensive benefits in glycemic control, weight reduction and hepato-cardio-renal metabolic indicators.

China has the highest number of T2D affected patients, facing urgent challenges in long-term glucose management and complication prevention

China leads the world in diabetes prevalence, with 140 million adults affected (1 in 4 global cases). Diabetes is a chronic condition where prolonged hyperglycemia can lead to severe complications, such as cardiovascular diseases, nephropathy, retinopathy and neuropathy. These complications not only endanger patients’ lives and health but also impose a significant economic burden on families and society.

In recent years, the treatment paradigm for diabetes has progressively shifted from glycemic control alone to a comprehensive, patient-centric management strategy. This approach integrates glycemic control, weight management, cardiovascular risk factor mitigation, and prevention/treatment of hepato-cardio-renal complications.

The ADA/EASD Consensus Report on the Management of Hyperglycemia in T2D has formally recognized weight reduction as a core therapeutic target. Weight loss should be prioritized not only to improve glycemic outcomes but also to reduce the risk of weight-related complications. For some patients with T2D, achieving a 5%–15% reduction in body weight is recommended as a primary treatment goal.

Mazdutide: superior glycemic control and weight loss, with hepato-cardio-renal metabolic benefits, supporting Healthy China 2030

Building upon the established effects of GLP-1 receptor agonists, dual GCG/GLP-1 receptor agonists simultaneously improve the two core pathogenic mechanisms of diabetes – insufficient insulin secretion and insulin resistance, thus, delivering comprehensive benefits beyond glycemic control, including weight loss, and hepato-cardio-renal metabolic improvements. As a safe, effective and convenient novel therapeutic option, mazdutide addresses the critical needs of long-term glucose management and complication prevention in T2D, actively supporting the realization of the “Healthy China 2030” vision.

The approval was based on two Phase 3 clinical trials (DREAMS-1 [NCT05628311] and DREAMS-2 [NCT05606913]), which evaluated the efficacy and safety of mazdutide as monotherapy and in combination with oral antidiabetic drugs, respectively, in Chinese participants with T2D. These studies demonstrated mazdutide’s superiority over placebo or dulaglutide 1.5 mg in glycemic control and weight reduction, while also showing improvements in multiple cardiometabolic, hepatic and renal parameters.

  • DREAMS-1: for the efficacy estimand, at Week 24, the mean changes in HbA1c from baseline in the mazdutide 4 mg group, mazdutide 6 mg group and placebo group were -1.57%, -2.15%, and -0.14%, respectively; the proportion of participants with HbA1c <7% were 68.6%, 87.4% and 10.7%, respectively; the mean percent change in body weight from baseline were -5.61%, -7.81% and -1.26%, respectively; and the proportion of participants with HbA1c <7% and a body weight reduction≥5% were 40.6%, 64.9%, and 0%, respectively.
  • DREAMS-2: for the efficacy estimand, at Week 28, the mean changes in HbA1c from baseline in the mazdutide 4 mg group, mazdutide 6 mg group and dulaglutide 1.5 mg group were -1.69%, -1.73% and -1.38%, respectively; the proportion of participants with HbA1c <7% were 71.2%, 74.2% and 62.1%, respectively; the mean percent change in body weight from baseline were -7.31%, -9.24% and -2.86%, respectively; and the proportion of participants with HbA1c <7% and a body weight reduction≥5% were 50.1%, 64.3%, and 19.4%, respectively.

Mazdutide exhibited a safety profile consistent with previous clinical studies and other GLP-1R agonists, with no new safety signals identified.

DREAMS-1 results were orally presented (Abstract #: 306-OR) at the 85th Scientific Sessions of the ADA; DREAMS-2 results were presented as a late-breaking oral presentation (Abstract #: LBA 16) at the 60th Annual Meeting of the EASD. Based on the innovative mechanism and robust evidence of mazdutide, it has been recommended in expert consensus in China..

It is worth noting that the mazdutide injection device demonstrates significant improvements in both convenience and safety compared to existing injection devices of the same type. The device features a hidden needle, ensuring the needle remains out of sight throughout the process, effectively reducing patient anxiety associated with injections. Additionally, it is a single-use device, designed for immediate disposal after use, which significantly lowers the risk of drug contamination caused by reuse or improper handling. Furthermore, the injection device incorporates innovative X-cross-section technology, delivering a smoother and painless injection experience, thereby enhancing patient comfort and treatment adherence.

Professor Dalong Zhu, the Principal Investigator of DREAMS-1 study, Nanjing University Affiliated Drum Tower Hospital, said: “China has a high prevalence of T2D globally, with over 140 million adult patients. A significant proportion of these individuals also suffer from overweight or obesity, cardiovascular diseases, and/or kidney diseases, making prevention and treatment particularly challenging. Mazdutide, as a dual GCG/GLP-1 receptor agonist, demonstrated superior efficacy in glycemic control and weight reduction compared to placebo in the DREAMS-1 study in Chinese patients with T2D inadequately managed by diet and exercise alone. It also showed a favorable safety profile. Additionally, mazdutide offered improvements such as reduced waist circumference, blood pressure and lipid levels. I am pleased to see mazdutide’s pivotal clinical study results in T2D patients have gained approval from national regulatory authorities, culminating in its market authorization, which could offer a new treatment option for T2D patients in China.”

Professor Jiajun Zhao, the Principal Investigator of DREAMS-1 study, Shandong Provincial Hospital, said: “In recent years, the treatment for diabetes has gradually shifted from mere glycemic control to a ‘patient-centered’ approach, integrating glycemic control, weight management, cardiovascular risk factor management, and addressing cardiorenal comorbidities and complications. GLP-1 receptor agonists not only excel in glycemic control but also effectively reduce weight, making them a hotspot and frontier in metabolic disease drug development. The Phase 3 study of mazdutide in participants with T2D has once again confirmed its outstanding efficacy in glycemic control and weight reduction, along with multiple metabolic benefits and a favorable safety profile. I am delighted to see the approval of mazdutide for the indication of glycemic control in adults with T2D, and I hope it will bring significant benefits to patients with T2D in China.”

Professor Lixin Guo, the principal investigator of the DREAMS-2 study, Beijing Hospital, said: “China has a high prevalence of T2D, yet the overall glycemic control rate among patients remains suboptimal. Many patients also accompany multiple cardiovascular risk factors such as obesity, hyperlipidemia, coronary heart disease, fatty liver disease, and renal diseases, which not only increase disease burden but also complicate treatment. There is an urgent clinical need for innovative therapies that demonstrate proven efficacy, favorable safety, convenient administration, and multiple cardiovascular benefits. The Phase 3 clinical study results of mazdutide in Chinese participants with T2D demonstrated not only significant glucose-lowering efficacy but also showed potential superiority over the dulaglutide in weight reduction. The approval of mazdutide for glycemic control in adults with T2D will provide more treatment options to Chinese T2D patients.”

Professor Wenying Yang, the principal investigator of the DREAMS-2 study, China–Japan Friendship Hospital, said: “In recent years, GLP-1 receptor agonists have emerged as superior therapeutic options for T2D patients by delivering comprehensive benefits in glycemic control, weight management, and cardiovascular/renal outcomes. As the first approved dual GCG/GLP-1 receptor agonist, Mazdutide demonstrated better efficacy than dulaglutide in both glucose-lowering and weight reduction during Phase 3 study in participants with T2D, while also showing multiple metabolic advantages and favorable safety profiles. These robust clinical results support its application as a next-generation GLP-1-based therapy for Chinese patients with T2D. I am delighted that Mazdutide has entered clinical practice, offering a novel treatment alternative for eligible T2D patients and contributing to improved clinical outcomes in diabetes management.”

Dr. Lei Qian, Chief R&D Officer of General Biomedicine from Innovent Biologics, stated, “Mazdutide represents the next-generation dual GCG/GLP-1 receptor agonist. Multiple clinical studies of mazdutide conducted in Chinese adults with T2D have demonstrated mazdutide’s exceptional dual advantages in both glycemic control and weight reduction across two major patient populations—those receiving monotherapy and those failing on multiple oral antidiabetic drugs. The treatment has shown multiple metabolic benefits for cardiovascular, hepatic and renal systems while maintaining an excellent safety profile. The successful approval of mazdutide reflects the national drug regulatory authority’s strong endorsement of its clinical value and safety profile, while fully validating Innovent Biologics’ innovative R&D capabilities in metabolic therapeutics. We hope mazdutide will provide superior treatment options for Chinese patients with T2D and help alleviate the disease burden on our society.”

About Diabetes

According to the 2021 global diabetes overview by the International Diabetes Federation, China leads the world in the number of patients with diabetes, with an estimated 140 million cases in 2021 and projected to reach 174 million by 2045[1]. Poor glycemic control can lead to irreversible microvascular and macrovascular complications, including reduced visual acuity, blindness, renal dysfunction, peripheral neuropathy, myocardial infarction, stroke and amputation[2]. The high prevalence of diabetes and its serious complications pose a significant threat to human health. Currently, various therapeutic approaches are available for diabetes management. In addition to controlling blood glucose, new hypoglycemic drugs are being developed to offer additional benefits such as weight loss, cardiovascular risk reduction and kidney protection[3].

About Mazdutide

Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of mazdutide, a dual GCG /GLP-1 receptor agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, in addition to the effects of GLP-1 receptor agonists on promoting insulin secretion, lowering blood glucose and reducing body weight, mazdutide may also increase energy expenditure and improve hepatic fat metabolism through the activation of glucagon receptor. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies, as well as reducing waist circumference, blood lipids, blood pressure, serum uric acid, liver enzymes, liver fat content and improved insulin sensitivity.

Mazdutide has conducted seven Phase 3 clinical studies, including:

  • GLORY-1: A Phase 3 clinical study conducted in Chinese adults with overweight of obesity;
  • GLORY-2: A Phase 3 clinical study conducted in Chinese adults with moderately to severely obesity;
  • GLORY-3: A Phase 3 clinical study comparing mazdutide versus semaglutide in Chinese adults with overweight of obesity accompanied metabolic-associated fatty liver disease (MAFLD);
  • GLORY-OSA: A Phase 3 trial in Chinese participants with obstructive sleep apnea (OSA) and obesity;
  • DREAMS-1: A Phase 3 clinical study conducted in Chinese adults with untreated type 2 diabetes;
  • DREAMS-2: A Phase 3 clinical study comparing mazdutide versus dulaglutide in Chinese adults with type 2 diabetes who have poor glycemia control with oral medication;
  • DREAMS-3: A Phase 3 clinical study comparing mazdutide versus semaglutide in Chinese adults with type 2 diabetes and obesity;

Among these, GLORY-1, DREAMS-1, and DREAMS-2 have already met their primary endpoints and the other four studies are currently ongoing.

In addition, several new clinical studies of mazdutide are initiated or planned, including:

  • A Phase 3 trial in adolescents with obesity;
  • New studies in patients with metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF).

*Mazdutide has received NMPA approval for two indications:

First Indication: as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of:

  • BMI ≥ 28 kg/m² (obesity); or
  • BMI ≥ 24 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hyperglycemia, hypertension, dyslipidemia, fatty liver, or obstructive sleep apnea syndrome and etc.);

Second Indication (Newly Approved): glycemic control in adults with type 2 diabetes:

Monotherapy

For adults with type 2 diabetes who have inadequate glycemic control despite diet and exercise interventions.

Combination Therapy

For adults with T2D who still have poor glycemic control despite:

Diet and exercise, plus Metformin and/or sulfonylureas, or Metformin and/or SGLT2 inhibitors (SGLT2i).

About Innovent Biologics

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:  Innovent does not recommend the use of any unapproved drug (s)/indication (s).

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References

[1].     Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projects for 2045 [published correction appeals in Diabetes Res Clin Pract. 2023 Oct; 204: 110945]. Diabetes Res Clin Pract. 2022; 183: 109119. doi: 10.1016/j.diabres.2021. 109119

[2].     Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. Published online 2016. doi: 10.1016/S2213-8587 (16) 30010-9

[3].     Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art. Mol Metab. Published online 2020. doi: 10.1016/j.molmet.2020. 101102

 

KuCoin Futures Implements Trading Upgrade for Improved Execution and Risk Management

PROVIDENCIALES, Turks and Caicos Islands, Sept. 19, 2025 /PRNewswire/ — KuCoin, a leading global cryptocurrency platform built on trust, is proud to announce that KuCoin Futures has rolled out an integrated system upgrade tailored to professional and high-frequency trading needs. It emphasizes faster execution, more reliable risk controls, efficient capital use, and a smoother user experience. The update optimizes key stages in the trading process and adds four features: Pre-Market Futures, Hedge Mode, One-Tap Reverse, and Market Close. These reduce operational steps and enhance trade reliability amid market fluctuations.

The upgrade rebuilds core infrastructure around execution certainty, drawing on user feedback from ongoing dialogues to address frontline needs through rapid product iterations and release cadence. Pre-Market Futures support early price discovery and hedging; Hedge Mode allows side-specific position handling with separate fees and liquidations to boost efficiency and curb risks; One-Tap Reverse streamlines direction changes; and Market Close enables closing all open orders at once at market price to quickly reduce exposure. Together, they cut latency and slippage while aligning risk and action.

Jack, Global Head of Business at KuCoin Futures, said: “Our progress is inseparable from user support; we always focus on users’ trading experience. At every stop of the Global Tour, we conduct one-to-one reviews with partners and professional traders, turning the most urgent pain points into a clear product task list. The consolidated launch of four capabilities puts ‘faster execution, more stable risk control, and higher capital efficiency’ into actual tools, helping users make more certain decisions in volatile conditions. Next, we will maintain high-frequency iterations and a closed feedback loop, moving from ‘usable’ to ‘easy to use,’ and then to ‘frequently used.'”

Since Q2, KuCoin Futures has noted steady growth in user activity and platform metrics, underscoring the value of user-focused improvements. At the same time, KuCoin Futures is certified No. 4 globally by Coinglass, and its CMC derivatives ranking continues to trend upward.

Going forward, KuCoin Futures will pursue combined offline engagement and online refinements in matching, risk models, fees, and usability. The features are live on web and app; see in-platform details for access. KuCoin Futures is committed to practical tools and sustainable market growth.

Disclaimer

This press release may include information from third-party or commercial sources, is provided for reference only and does not constitute financial or investment advice, an offer, solicitation, or guarantee. We disclaim liability for any losses that may result from reliance on this information. Investments and trading involve risks, and past performance does not guarantee future results. Users should conduct their own research, exercise prudence, and assume full responsibility for their decisions. Products or services referenced herein may not be available in all regions. For details, please refer to the Terms of Use and Risk Disclosure.

About KuCoin Futures

Launched in 2019, KuCoin Futures is the derivatives arm of KuCoin, offering a wide range of perpetual and quarterly contracts across major cryptocurrencies. Built for both retail and institutional users, KuCoin Futures delivers a powerful and intuitive trading experience backed by robust liquidity and advanced risk management systems. The platform supports cross-margin and isolated-margin modes, customizable leverage, and a comprehensive API, making it one of the most user-friendly and scalable derivatives platforms in the industry.

To learn more, visit https://www.kucoin.com/futures

Shanghai hosts Global Gen Z Forum showcasing people-oriented urban innovation

SHANGHAI, Sept. 19, 2025 /PRNewswire/ — A news report from english.shanghai.gov.cn

Gen Zers from various countries gather for a round-table dialogue at Yangpu's V-Hub in Shanghai on Sept 14, 2025. [Photo by Dong Ming/For China Daily]
Gen Zers from various countries gather for a round-table dialogue at Yangpu’s V-Hub in Shanghai on Sept 14, 2025. [Photo by Dong Ming/For China Daily]

Shanghai’s Yangpu Riverside welcomed dozens of young people from around the world for the Global Generation Z Forum on Innovative Coexistence in People-Oriented Cities on Sept 14.

Generation Z generally refers to those born from the mid-1990s to the early 2010s. The forum offered participants an immersive journey through some of the city’s most iconic urban regeneration sites.

Using the “Travel in Shanghai” section of the International Services Shanghai online portal, they planned their own waterfront walking routes.

“With this portal, I can now forward English-language information directly to my guests, something that was impossible a few years ago,” said Clarisse Le Guernic, a French cultural entrepreneur who introduces Shanghai’s history through city walks, on-site explorations, and cultural parkour challenges for international visitors.

At the Yangshupu Power Plant Relics Park, international youth learned how the century-old industrial landmark has been transformed into a vibrant public space that embodies low-carbon and sustainable development.

The tour continued to the WorldSkills Museum, where participants tried out the “Fuxing Bullet Train” simulator and the “Yangpu Riverside Cycling” digital ride.

Next, at the Shanghai People’s City Practice Exhibition Hall, they interacted with the AI digital host “Shen Yang” to learn more about the “Work in Shanghai” initiative. There, they explored the International Services Shanghai portal’s “Work in Shanghai” and “Study in Shanghai” sections to discover job opportunities, academic programs, and policies for international talent.

“I started using the platform quite recently, and it’s really convenient now that there’s just one website that provides all your answers, from travel needs, to work needs, to life needs, to just about anything you can think of,” said Conor Weeks from the United States, who is planning to work in China.

Filip Filipovic, a Serbian entrepreneur based in Shanghai who decided to start up a company with a friend, added, “I first researched the paperwork in Chinese, but the information was scattered. On this International Services Shanghai platform, all the details for foreigners are in one place, so the process became really smooth.”

A round-table dialogue capped the event, where Chinese and international youth shared their “first encounters with China“, discussed how technology can enhance public services, and envisioned more inclusive, multicultural communities.

Aleksandra Antonenko, a Russian entrepreneur and content creator, said, “Observing young people from diverse backgrounds engage, exchange ideas, and learn from one another highlights the power of cross-cultural dialogue. Shanghai demonstrates how a city can foster such meaningful connections, and the International Services Shanghai portal sets a strong example for inclusive and forward-looking urban communities.”

The event offered a vivid demonstration of Shanghai’s “People’s City” philosophy and achievements in digital innovation, while giving the next generation of global citizens a platform to contribute fresh ideas and international perspectives to the city’s ongoing transformation.

Experience the Best of Canggu at Citadines Berawa Beach Bali

BALI, Indonesia, Sept. 19, 2025 /PRNewswire/ — Welcome to Canggu, Bali’s most vibrant coastal hotspot, where every sunrise invites adventure and every sunset leaves lasting memories. At Citadines Berawa Beach Bali, you’re at the heart of it all. Just steps from Berawa Beach, the hotel is surrounded by world-class surf breaks, buzzing beach clubs, family-friendly hangouts, and pet-friendly spaces. Here, comfort, convenience, and style come together for every kind of traveler.

Citadines Berawa Beach Bali – Hotel in Canggu
Citadines Berawa Beach Bali – Hotel in Canggu

Once a quiet fishing village, Canggu has grown into a lively hub for explorers of all kinds. Digital nomads, families, surfers, runners, and pet lovers all find their rhythm here. Mornings often begin with a run along the coast or a surf session at Batu Bolong or Echo Beach. Afternoons offer beach volleyball, padel session, coastal jogs, and café hopping. The options are endless, and the energy never fades.

As the sun sets, Canggu transforms into a nightlife destination, home to iconic venues like La Brisa, The Lawn, Times Beach Warung, Finns Beach Club, and Atlas Beach Club. Each just minutes from Citadines Berawa Beach Bali. From bohemian beachfront lounges to high-energy entertainment spaces and authentic local flavors, there’s always something new to discover. Guests at Citadines Berawa Beach Bali can enjoy even more value during their stay with exclusive benefits at select partner venues simply by presenting their room key card.

Life in Canggu isn’t just about the beaches. Digital nomads stay connected with high-speed WiFi and coworking hubs. Families enjoy kid-friendly activities, sports, and adventures perfectly timed with Bali’s sunny season. Pet owners discover a welcoming community, making traveling with furry friends seamless and enjoyable.

Citadines Berawa Beach Bali truly brings it all together, offering the perfect balance of comfort, convenience, and lifestyle. Our serviced residences are designed to suit every type of stay, whether it’s a short getaway, an extended stay, or something in between. Each residence is equipped with a kitchenette, giving guests the flexibility to enjoy home-style dining at their convenience, while high-speed internet access ensures seamless connectivity for both work and leisure.

Guests can relax and recharge at our rooftop infinity sky pool, where panoramic views of Canggu create unforgettable moments. Wellness is also at the heart of our property, with a dedicated yoga deck and a fully equipped gym available for daily routines. For families, we provide a kids’ playground, while our pet playground welcomes four-legged family members — reflecting our commitment as a truly pet-friendly hotel. Practical conveniences such as 24/7 security and launderette facilities make life easier for long-stay residents, ensuring peace of mind and day-to-day comfort. At Citadines Berawa Beach Bali, every detail is designed to create a base where work, play, and relaxation come together effortlessly.

Whether you’re chasing waves, working with the ocean as your backdrop, exploring with family, or living the Bali dream with your pet, Citadines Berawa Beach Bali gives you the best of Canggu. Every sunrise, every sunset, every moment. Book your stay at www.discoverasr.com, call us at +62 361 9090 099 or WhatsApp +62 8113 9619 099.

Don’t just visit Canggu. Live it !

About The Ascott Limited

The Ascott Limited (Ascott) is a Singapore company that has grown to be one of the leading international lodging owner-operators. Ascott’s portfolio spans over 220 cities across over 40 countries in Asia Pacific, Central Asia, Europe, the Middle East, Africa, and the USA. 

Ascott has more than 94,000 operating units and about 64,000 units under development, making a total of more than 159,000 units in over 900 properties. 

The company’s serviced apartment, coliving and hotel brands include Ascott, Citadines, lyf, Oakwood, Quest, Somerset, The Crest Collection, The Unlimited Collection, Préférence, Fox, Harris, POP!, Vertu and Yello. 

Ascott’s loyalty programme, Ascott Star Rewards, offers exclusive benefits to its members when they book directly with Ascott for their stays at its participating properties. 

Ascott, a wholly owned subsidiary of CapitaLand Investment Limited, pioneered Asia Pacific’s first international-class serviced apartment with the opening of The Ascott Singapore in 1984. Today, the company boasts over 30 years of industry track record and award-winning brands that enjoy recognition worldwide. 

For more information, please visit www.discoverasr.com 

About CapitaLand Investment Limited

Headquartered and listed in Singapore, CapitaLand Investment Limited (CLI) is a leading global real estate investment manager (REIM) with a strong Asia foothold.  As at 30 September 2022, CLI had about S$130 billion of real estate assets under management, and about S$86 billion of real estate funds under management (FUM) held via six listed real estate investment trusts and business trusts, and about 30 private vehicles across Asia-Pacific, Europe and USA.  Its diversified real estate asset classes cover retail, office, lodging, business parks, industrial, logistics and data centres.

CLI aims to scale its FUM and fee-related earnings through fund management, lodging management and its full stack of operating capabilities, and maintain effective capital management.  As the investment management arm of CapitaLand Group, CLI has access to the development capabilities of and pipeline investment opportunities from CapitaLand’s development arm. 

As a responsible company, CLI places sustainability at the core of what it does and has committed to achieve net zero emissions by 2050.  CLI contributes to the environmental and social well-being of the communities where it operates, as it delivers long-term economic value to its stakeholders.

For more information, please visit http://www.capitalandinvest.com/

HUAWEI SOUND ULTIMATE Series: Defining a New Era of Smart In-Car Audio


SHANGHAI, CHINA – Media OutReach Newswire – 19 September 2025 – Huawei’s acoustic experts shared insights into the advanced technology chain behind the HUAWEI SOUND ULTIMATE Series, and shares the R&D journey that shaped its signature sound quality at the HUAWEI SOUND In-Car Audio Experience Event. Held at Huawei’s Shanghai Acoustics R&D Center, the event invites media guests to tour the labs and experience the system first-hand in Maextro S800, the ultra-luxury sedan, delivering an immersive showcase of sight and sound.

HUAWEI SOUND ULTIMATE Series: Defining a New Era of Smart In-Car Audio

Building on its sustained, high-intensity investments and research into audio technology since 2012, Huawei is addressing growing consumer demands for exceptional audio experiences. Huawei’s decades of expertise in hardware engineering and software algorithms, combined with artistic tuning by a team of top-tier sound engineers, forge an unparalleled audio experience for HUAWEI SOUND. With the launch of the Maextro S800 featuring the top-tier HUAWEI SOUND ULTIMATE series this year, it also marks the rise of the Chinese-developed in-car audio system, surpassing those of long-established competitors from all over the world.

The HUAWEI SOUND ULTIMATE Series is HUAWEI’s most luxurious audio system to date, featuring a rare industry-leading configuration of 43 speakers to create an ultra-surround acoustic design needed to support all features for the sound system. It supports 2920 W dual amplifiers for stronger power and more impactful sound, and introduces rear 4D exciters that synchronize with music and video content to create a fully immersive, multi-sensory experience. Integrating Huawei’s cutting-edge hardware, technologies, and algorithms, the HUAWEI SOUND ULTIMATE Series delivers an industry-first seat-specific 4D immersive surround sound experience.

HUAWEI SOUND ULTIMATE Series debuts the Crystal Star-Ring Diffuser, which automatically rises to greet users as they enter, with ambient lighting that moves in sync with the music. Its precision-crafted structure delivers clear center information when needed, with 30 percent greater sound uniformity over the previous generation, creating a truly luxurious listening experience. The Series also introduces the innovative Tangential Force Woofer, an industry-first design that rotates the conventional door woofer by 90 degrees to reduce panel resonance while extending bass response for deeper, purer low frequencies. Completing the lineup, the patented Dual-Diaphragm Subwoofer uses an ingenious dual-diaphragm acoustic design that breaks free from traditional cavity constraints, harnessing the surrounding cabin space to deliver the deepest bass extension in its class, with remarkable layering and greater impact.

The HUAWEI SOUND ULTIMATE Series also demonstrates its strong technological capabilities through its listening performance. It debuts 4-seat, 4-headrest speaker system and pioneers independent sound zone technology: powered by Huawei’s proprietary sound field control algorithms, the vehicle’s speakers can instantly act as silencers, achieving 30 dB isolation between front and rear sound fields and 99% energy separation, so passengers in each row can enjoy separate audio information with less interference. With 10 overhead channels, adaptive sound field control, and Huawei’s proprietary spatial audio track model, the Series delivers spatial audio with greater clarity and more precise positioning.

In smart ambience, HUAWEI SOUND is continuously expanding a HarmonyOS-based content ecosystem that brings users a premium end-to-end audio-visual experience. With AI-powered “sound-to-light” technology, ambient lighting moves in sync with the music, giving the cabin a richer emotional quality where every note can not only be heard, but seen.

At the event, Lars Goller, Chief Automotive Sound & Acoustics Advisor, Huawei shared his goal for the in-car audio tuning is to recreate “an optimum reproduction of the recording, to bring us closer to the experience the artist intended. By marrying the science of psychoacoustics with exquisite tuning and a foundation of bespoke high-performance hardware, HUAWEI SOUND aims to bring the outstanding phantom effect of sitting right where the music was created to the car users”.

Looking ahead, HUAWEI SOUND will continue to evolve and innovate, pushing boundaries in the world of sound. By uniting technology with artistry, it aims to deliver an extraordinary in-cabin experience for every user.
Hashtag: #Huawei #HUAWEISOUNDULTIMATE

The issuer is solely responsible for the content of this announcement.

Club Med’s 2026 Summer Getaways: Endless fun from the Mountains to the Sea

HO CHI MINH CITY, Vietnam, Sept. 19, 2025 /PRNewswire/ — A pioneer of premium all-inclusive holidays for the last 75 years, Club Med has consistently evolved to meet the needs of today’s travellers, be it reconnecting with loved ones, exploring lesser-known destinations, or finding meaningful moments in lush nature. From brand-new resorts to thoughtfully refreshed favourites, summer is the season to embrace the glorious sunshine and the simple joy of being present.

Club Med's premium all-inclusive escapes for May to November 2026, open for reservations 14 October 2025
Club Med’s premium all-inclusive escapes for May to November 2026, open for reservations 14 October 2025

Opening the season on 14 October 2025 will be the highly anticipated two weeks of “price guarantee” – our commitment to making holidays even more magical, where decisive reservations are rewarded with the best possible price, across the vast selection of resorts and destinations globally. For those who appreciate more time, another six weeks of “discount guarantee”, from 01 November 2025 will help ensure that holidaymakers still enjoy the best possible discount for the season.

Looking ahead to Summer 2026, Club Med invites multi-generational families, adventure seekers, nature lovers and wellness enthusiasts, to discover an extraordinary collection of experiences across the globe.

In Asia, Club Med Phuket introduces its brand-new Family Oasis, complete with spacious rooms, a splash park and lush gardens designed for carefree bonding. In addition to this new zone, the resort is also refreshing its existing accommodations, with renovations scheduled for completion by December 2025. Highland escapes await at Club Med Tomamu, Japan and Club Med Lijiang, China, where days unfold amid wildflower meadows or along cobblestone streets of Lijiang’s UNESCO-listed Old Town. For barefoot luxury, the Maldives’ Club Med Kani enchants with its iconic overwater villas and vibrant marine life.

In Europe, Club Med Cefalù radiates Sicilian elegance; Club Med 2, the brand’s elegant five-masted yacht, sails into iconic Mediterranean ports, while Club Med Marrakech La Palmeraie and Club Med Serre Chevalier celebrate Moroccan culture and French Alpine beauty.

Across the Americas, Club Med Punta Cana, Club Med Turkoise, Club Med Cancun and Club Med Québec Charlevoix promise escapes as diverse as they are unforgettable, from Caribbean rhythms to Mayan culture, Mexican flavours and adventurous outdoor activities in the North America.

Be it a serene beach retreat, culturally immersive journey, or an adrenalin-pumping family adventure, Club Med offers the freedom to enjoy hassle-free holidays with complete peace of mind. Enjoy exclusive early bird savings of up to 30 percent off your next summer vacation from 14 October 2025 to 28 April 2026.

Disclaimer: This media release is distributed in the Vietnam region; the booking terms and conditions may only apply to specific markets. Additionally, this release is available for pickup by other regional news channels, offering opportunities for broader coverage and increased visibility. 

DarwinCell Showcases novel MSC-based drug ALT001 at the 150th American Neurological Association Annual Meeting

BALTIMORE, Sept. 19, 2025 /PRNewswire/ — The 150th American Neurological Association Annual Meeting (ANA 2025) was successfully held in Baltimore, USA, from September 13 to 16, 2025. The conference brought together leading global experts, scholars, and industry leaders in the field of neuroscience to discuss the latest research advances and therapeutic strategies for neurological diseases. DarwinCell delivered an oral presentation in the “Neuromuscular Disease SIG” session and presented a poster showcasing the latest research data on its novel MSC-based drug ALT001 for the treatment of amyotrophic lateral sclerosis (ALS). The company’s poster, recognized for its innovation and scientific value, received the “Abstract of Distinction” at this year’s Annual Meeting and attracted wide attention on site.

Clinically, ALS is characterized by progressively developing skeletal muscle weakness, atrophy, fasciculations, bulbar palsy, and pyramidal tract signs, ultimately leading to death due to respiratory and circulatory system failure. The age of onset is trending younger, with a minority of patients developing symptoms as early as around 20 years old [1]. The incidence of ALS in China is approximately 0.6 per 100,000 people, with a prevalence of about 3.1 per 100,000 and a typical survival period of 3-5 years [2-5]. Currently, the primary treatments available in China are still Riluzole and Edaravone [4], highlighting an urgent need for new therapeutic approaches.

ALT001 demonstrates promising clinical benefits. Both in vitro studies and IIT studies on more than 40 ALS patients are conducted. In vitro experiments showed that cells treated with ALT001 restored cell viability after oxidative damage. Progressive loss of anterior horn motoneurons and muscle atrophy due to the lack of neuronal innervation are hallmarks of ALS. We found that ALT001 protected motoneurons against neurotoxicity, and ameliorated muscle atrophy in SOD1G93A mice. In agreement with these results, the mutant mice treated with ALT001 exhibited improved motor functions and extended lifespan in comparison to mice treated with vehicle or Riluzole. We then carried out multiple IITs including a double-blinded study on the safety and the efficacy of ALT001 on ALS patients. After 2-weeks of administration of ALT001, most patients reported positive outcomes, as demonstrated by elevated performance, ALSFRS-R and modified Norris scores. 

We are greatly honored to share the latest data on ALT001 at this global academic forefront conference,” said Ms. Wang Yu, Founder and CEO of DarwinCell. “These results reinforce our confidence in further developing ALT001 for ALS and other major neurological diseases. ALT001 is designed to combine the functional diversity of cell therapies with the practicality of traditional biologics, aiming to provide patients with more effective, safer, and accessible treatment options. The company remains committed to being clinically-oriented and driven by scientific innovation, continuously deepening our presence in neuroscience and regenerative medicine. Darwin will fully advance the IND application processes for ALT001 in both China and the U.S., hoping to bring new hope to patients worldwide as soon as possible.”

About DarwinCell

DarwinCell founded in 2016, is a national high-tech enterprise focused on innovative treatments for neurological diseases. Leveraging its proprietary protein polymer extraction technology (ECIWEP), the company has built a comprehensive technology platform from drug discovery to clinical translation. Through deep collaborations with numerous leading medical and research institutions, DualityBio is dedicated to becoming an internationally leading innovator in neural repair technology. For more information, please visit https://darwincell.net/en.

Reference

[1]Chinese Society of Neurology, Amyotrophic Lateral Sclerosis Collaboration Group. (2022). Chinese Expert Consensus on the Diagnosis and Treatment of Amyotrophic Lateral Sclerosis (2022). Chinese Journal of Neurology, 55(6), 8.

[2]Feldman EL, Goutman SA, Petri S, et al. Amyotrophic lateral sclerosis. *Lancet*. 2022;400(10360): 1363-1380.

[3]van Es MA,Hardiman O,Chio A,et al. Amyotrophic lateral sclerosis[J].Lancet,2017,390 (10107):2084-2098.

[4]NORRIS S P, LIKANJE M N, ANDREWS J A. Amyotrophic lateral sclerosis: update onclinicalmanageme nt[J]. Curr Opin Neurol. 2020; 33(5):641- 648.

[5]Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. *Handb Clin Neurol*. 2016;138: 225-238.